Latest Non Dilutive Funding News

Neurizon Therapeutics has secured a $1.5 million loan against its expected 2025 R&D tax rebate, boosting liquidity without diluting shareholders. This strategic move supports ongoing development of its neurodegenerative disease treatments.

Actinogen Medical has reached a key milestone in its XanaMIA phase 2b/3 Alzheimer’s trial with over 100 participants enrolled, setting the stage for an interim analysis in January 2026. The company also secured a $13.8 million non-dilutive R&D funding facility to support ongoing development.

Noxopharm has initiated its HERACLES clinical trial for SOF-SKN, marking a key milestone for its Sofra platform, while deepening partnerships and actively seeking new funding to sustain development.

EMVision Medical Devices reports strong progress in its pivotal trial for the emu™ bedside brain scanner and successful aeromedical testing of its First Responder device, backed by a $5 million government grant and $10.5 million in cash reserves.

International Graphite Limited has partnered with Arctic Graphite AS to establish a new expandable graphite facility in Germany, aiming to bolster European supply with an initial 3,000 tonnes per year capacity. Backed by a potential $10 million funding commitment, this venture marks a strategic push into critical mineral processing amid rising demand.

Winsome Resources progresses key permitting and exploration milestones at its Adina Lithium Project while maintaining a strong cash position and deferring the Renard Option decision amid subdued lithium market conditions.

Thor Energy has agreed to sell a majority stake in its US uranium projects to Metals One, securing upfront cash and stock consideration while focusing on its hydrogen and helium ambitions.

Zelira Therapeutics has locked in a $650,000 loan facility secured against its anticipated FY25 R&D tax rebate, aiming to accelerate its HOPE SPV clinical trial and strengthen working capital.

Argenica Therapeutics has dosed the final patient in its Phase 2 trial for ARG-007 in acute ischaemic stroke, with topline results expected in Q3 2025. Meanwhile, the FDA has placed a clinical hold on its US trial application, introducing uncertainty for US development.

Nyrada Inc. is set to launch a Phase IIa clinical trial of Xolatryp™, aiming to reduce heart muscle damage in acute myocardial infarction patients undergoing PCI. The trial, planned for early 2026, follows promising Phase I safety results and strong preclinical cardioprotection data.

4DMedical has renewed its three-year contract with the University of Michigan Medical Center, reinforcing its foothold in US respiratory imaging. Alongside, a pivotal clinical study validates its technology’s ability to detect early lung disease, while a substantial Australian grant boosts its AI research.

Revolver Resources has completed critical engineering designs and secured over A$1 million in government grants and royalties, setting the stage for a targeted restart of copper production at its Dianne Copper Mine in late 2025.